CRISPR Market to Grow to $8,890 Million by 2035.
CRISPR market is expected to witness significant growth during the forecast period, driven by increasing advancements in genome editing technologies and rising investments in genetic engineering research. Growing adoption of CRISPR technologies across applications such as cell line engineering, gene libraries, genome editing, genetically modified crops, and human stem cell research is accelerating market expansion globally. Additionally, increasing demand for precision medicine, gene therapy development, and biotechnology innovation among academic institutes, biotechnology companies, pharmaceutical companies, and research organizations is further supporting market growth.
Browse the full report description of “CRISPR Market Size, Share & Trends Analysis Report by Application (Cell Line Engineering, CRISPR Plasmid, Gene Database/Gene Library, Genetic Engineering, Genetically Modified Organisms or Crops, Genome Editing, Human Stem Cells), and by End-User (Academic Institutes, Biotechnology Companies, Pharmaceuticals Companies, and Research and Development Institutes), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/crispr-market
Intellia Therapeutics – Phase 3 Advancement of NTLA-2002 (2025)
Intellia Therapeutics dosed the first patient in its global Phase 3 HAELO study for NTLA-2002 targeting hereditary angioedema (HAE). The development represents a major advancement in in vivo CRISPR gene-editing technology, where editing occurs directly inside the human body rather than through ex vivo cell modification. The therapy is designed as a one-time treatment aimed at reducing recurrent HAE attacks and improving long-term disease management. The milestone further strengthens clinical confidence in next-generation CRISPR therapeutics and expands the commercial potential of in vivo genome editing platforms.
?? Vertex Pharmaceuticals – NHS England Reimbursement Agreement for CASGEVY (2025)
Vertex Pharmaceuticals announced reimbursement access for CASGEVY through NHS England, enabling eligible sickle cell disease (SCD) patients to receive the CRISPR-based therapy under the national healthcare system. The agreement expands the real-world commercial rollout of gene-editing therapies following earlier reimbursement support for transfusion-dependent beta thalassemia (TDT). The development marks an important step toward broader healthcare adoption of high-cost gene-editing treatments and improves patient accessibility across Europe’s public healthcare market.
Vertex Pharmaceuticals and CRISPR Therapeutics – European Commission Approval for CASGEVY (2024–2025)
Vertex Pharmaceuticals and CRISPR Therapeutics received European Commission approval for CASGEVY (exa-cel), recognized as the world’s first approved CRISPR/Cas9 gene-edited therapy. The therapy was approved for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The approval represents the first large-scale commercial validation of CRISPR-based therapeutics and a major milestone in the global clinical adoption of gene-editing technologies. The decision is expected to accelerate investment, research activity, and commercialization efforts across the broader CRISPR therapeutics marke
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404